ClinicalTrials.Veeva

Menu

Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy

U

University Hospital, Lille

Status

Completed

Conditions

Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy

Study type

Observational

Funder types

Other

Identifiers

NCT03434795
2011_40
912180 (Other Identifier)
12-272 (Other Identifier)

Details and patient eligibility

About

Evaluate the reproducibility and validate a posteriori a new rule of clinical decision on a multi-center population of children with a post-chemotherapy febrile neutropenia

Enrollment

1,900 patients

Sex

All

Ages

1 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Child aged 1 to 18 years
  • Child with hematology or cancer
  • Child with a febrile neutropenia post-chemotherapy
  • Child with social security
  • No opposition from the child and/or parents, in case of absence, the holder of the parental authority present, can consent, alone, to the participation of the unemancipated minor.

Exclusion criteria

  • Febrile neutropenia at diagnosis of tumor disease
  • Child with palliative care
  • Child having had a hematopoietic stem cell allo-graft in the preceding year
  • Febrile neutropenia immediately post auto-transplant
  • Antibiotherapy prior to admission
  • Initial care in a non-investigative center.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems